nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—Lethargy—Spironolactone—dilated cardiomyopathy	0.00517	0.00845	CcSEcCtD
Mesalazine—Cholestasis—Furosemide—dilated cardiomyopathy	0.005	0.00817	CcSEcCtD
Mesalazine—Tubulointerstitial nephritis—Furosemide—dilated cardiomyopathy	0.00496	0.00811	CcSEcCtD
Mesalazine—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00456	0.00746	CcSEcCtD
Mesalazine—Psoriasis—Lisinopril—dilated cardiomyopathy	0.00453	0.00741	CcSEcCtD
Mesalazine—Gastritis—Spironolactone—dilated cardiomyopathy	0.00448	0.00733	CcSEcCtD
Mesalazine—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00434	0.00709	CcSEcCtD
Mesalazine—Jaundice cholestatic—Furosemide—dilated cardiomyopathy	0.00432	0.00706	CcSEcCtD
Mesalazine—Bone marrow depression—Lisinopril—dilated cardiomyopathy	0.00422	0.0069	CcSEcCtD
Mesalazine—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00415	0.00678	CcSEcCtD
Mesalazine—Gout—Furosemide—dilated cardiomyopathy	0.00407	0.00665	CcSEcCtD
Mesalazine—Throat sore—Lisinopril—dilated cardiomyopathy	0.00395	0.00646	CcSEcCtD
Mesalazine—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.00392	0.0064	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00387	0.00633	CcSEcCtD
Mesalazine—Renal failure—Spironolactone—dilated cardiomyopathy	0.00384	0.00627	CcSEcCtD
Mesalazine—Dopamine—SLC22A5—dilated cardiomyopathy	0.0038	0.302	CrCbGaD
Mesalazine—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.00372	0.00608	CcSEcCtD
Mesalazine—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00364	0.00596	CcSEcCtD
Mesalazine—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.00357	0.00583	CcSEcCtD
Mesalazine—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.00352	0.00575	CcSEcCtD
Mesalazine—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00349	0.0057	CcSEcCtD
Mesalazine—Bladder pain—Furosemide—dilated cardiomyopathy	0.00343	0.00561	CcSEcCtD
Mesalazine—Droxidopa—ADRB1—dilated cardiomyopathy	0.00336	0.266	CrCbGaD
Mesalazine—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00331	0.00542	CcSEcCtD
Mesalazine—Breast pain—Lisinopril—dilated cardiomyopathy	0.00327	0.00534	CcSEcCtD
Mesalazine—Proteinuria—Lisinopril—dilated cardiomyopathy	0.00324	0.0053	CcSEcCtD
Mesalazine—Jaundice cholestatic—Lisinopril—dilated cardiomyopathy	0.00324	0.0053	CcSEcCtD
Mesalazine—Protein urine present—Lisinopril—dilated cardiomyopathy	0.0032	0.00523	CcSEcCtD
Mesalazine—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00314	0.00513	CcSEcCtD
Mesalazine—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00313	0.00512	CcSEcCtD
Mesalazine—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00313	0.00512	CcSEcCtD
Mesalazine—Cough increased—Lisinopril—dilated cardiomyopathy	0.00311	0.00509	CcSEcCtD
Mesalazine—Alopecia—Spironolactone—dilated cardiomyopathy	0.0031	0.00506	CcSEcCtD
Mesalazine—Deafness—Furosemide—dilated cardiomyopathy	0.00308	0.00504	CcSEcCtD
Mesalazine—Gout—Lisinopril—dilated cardiomyopathy	0.00305	0.00499	CcSEcCtD
Mesalazine—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00303	0.00496	CcSEcCtD
Mesalazine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00293	0.0048	CcSEcCtD
Mesalazine—Thirst—Furosemide—dilated cardiomyopathy	0.0029	0.00473	CcSEcCtD
Mesalazine—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00288	0.00471	CcSEcCtD
Mesalazine—Neck pain—Lisinopril—dilated cardiomyopathy	0.00288	0.00471	CcSEcCtD
Mesalazine—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00288	0.00471	CcSEcCtD
Mesalazine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00283	0.00463	CcSEcCtD
Mesalazine—Droxidopa—ADRB2—dilated cardiomyopathy	0.00282	0.224	CrCbGaD
Mesalazine—Lethargy—Furosemide—dilated cardiomyopathy	0.00281	0.0046	CcSEcCtD
Mesalazine—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00278	0.00455	CcSEcCtD
Mesalazine—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00277	0.00452	CcSEcCtD
Mesalazine—Malaise—Spironolactone—dilated cardiomyopathy	0.00275	0.0045	CcSEcCtD
Mesalazine—Cystitis—Lisinopril—dilated cardiomyopathy	0.00275	0.0045	CcSEcCtD
Mesalazine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00273	0.00446	CcSEcCtD
Mesalazine—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00269	0.0044	CcSEcCtD
Mesalazine—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00267	0.00437	CcSEcCtD
Mesalazine—Dopamine—ADRB1—dilated cardiomyopathy	0.00263	0.208	CrCbGaD
Mesalazine—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00258	0.00422	CcSEcCtD
Mesalazine—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00258	0.00421	CcSEcCtD
Mesalazine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00257	0.0042	CcSEcCtD
Mesalazine—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00252	0.00412	CcSEcCtD
Mesalazine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00251	0.0041	CcSEcCtD
Mesalazine—Hypertonia—Lisinopril—dilated cardiomyopathy	0.0025	0.00408	CcSEcCtD
Mesalazine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00249	0.00407	CcSEcCtD
Mesalazine—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00248	0.00406	CcSEcCtD
Mesalazine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00244	0.00399	CcSEcCtD
Mesalazine—Abdominal distension—Furosemide—dilated cardiomyopathy	0.0024	0.00392	CcSEcCtD
Mesalazine—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00236	0.00386	CcSEcCtD
Mesalazine—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00236	0.00385	CcSEcCtD
Mesalazine—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00234	0.00382	CcSEcCtD
Mesalazine—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00233	0.00381	CcSEcCtD
Mesalazine—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.0023	0.00376	CcSEcCtD
Mesalazine—Eczema—Lisinopril—dilated cardiomyopathy	0.0023	0.00376	CcSEcCtD
Mesalazine—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00224	0.00366	CcSEcCtD
Mesalazine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00223	0.00365	CcSEcCtD
Mesalazine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00221	0.00362	CcSEcCtD
Mesalazine—Pollakiuria—Furosemide—dilated cardiomyopathy	0.0022	0.0036	CcSEcCtD
Mesalazine—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00218	0.00357	CcSEcCtD
Mesalazine—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00217	0.00355	CcSEcCtD
Mesalazine—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00217	0.00355	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00215	0.00351	CcSEcCtD
Mesalazine—Arthritis—Lisinopril—dilated cardiomyopathy	0.00213	0.00348	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00211	0.00344	CcSEcCtD
Mesalazine—Renal failure—Furosemide—dilated cardiomyopathy	0.00209	0.00341	CcSEcCtD
Mesalazine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00207	0.00338	CcSEcCtD
Mesalazine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00205	0.00335	CcSEcCtD
Mesalazine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00205	0.00335	CcSEcCtD
Mesalazine—Sweating—Furosemide—dilated cardiomyopathy	0.00204	0.00333	CcSEcCtD
Mesalazine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00201	0.00328	CcSEcCtD
Mesalazine—Face oedema—Lisinopril—dilated cardiomyopathy	0.002	0.00326	CcSEcCtD
Mesalazine—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00198	0.00324	CcSEcCtD
Mesalazine—Urticaria—Spironolactone—dilated cardiomyopathy	0.00198	0.00323	CcSEcCtD
Mesalazine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00197	0.00322	CcSEcCtD
Mesalazine—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00194	0.00317	CcSEcCtD
Mesalazine—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00189	0.00309	CcSEcCtD
Mesalazine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00188	0.00308	CcSEcCtD
Mesalazine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00187	0.00306	CcSEcCtD
Mesalazine—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00187	0.00306	CcSEcCtD
Mesalazine—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00186	0.00304	CcSEcCtD
Mesalazine—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00185	0.00302	CcSEcCtD
Mesalazine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00183	0.003	CcSEcCtD
Mesalazine—Gastritis—Lisinopril—dilated cardiomyopathy	0.00183	0.00299	CcSEcCtD
Mesalazine—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.0018	0.00295	CcSEcCtD
Mesalazine—Influenza—Lisinopril—dilated cardiomyopathy	0.00179	0.00292	CcSEcCtD
Mesalazine—Asthma—Lisinopril—dilated cardiomyopathy	0.00179	0.00292	CcSEcCtD
Mesalazine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00178	0.00291	CcSEcCtD
Mesalazine—Tinnitus—Furosemide—dilated cardiomyopathy	0.00178	0.00291	CcSEcCtD
Mesalazine—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00177	0.00289	CcSEcCtD
Mesalazine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00176	0.00288	CcSEcCtD
Mesalazine—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00176	0.00287	CcSEcCtD
Mesalazine—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00175	0.00286	CcSEcCtD
Mesalazine—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00174	0.00285	CcSEcCtD
Mesalazine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00173	0.00283	CcSEcCtD
Mesalazine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00172	0.00282	CcSEcCtD
Mesalazine—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00172	0.00281	CcSEcCtD
Mesalazine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.0017	0.00279	CcSEcCtD
Mesalazine—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.0017	0.00278	CcSEcCtD
Mesalazine—Dysuria—Lisinopril—dilated cardiomyopathy	0.00167	0.00273	CcSEcCtD
Mesalazine—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00167	0.00273	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00166	0.00272	CcSEcCtD
Mesalazine—Erythema—Furosemide—dilated cardiomyopathy	0.00166	0.00271	CcSEcCtD
Mesalazine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00165	0.00269	CcSEcCtD
Mesalazine—Flatulence—Furosemide—dilated cardiomyopathy	0.00164	0.00267	CcSEcCtD
Mesalazine—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00163	0.00267	CcSEcCtD
Mesalazine—Weight increased—Lisinopril—dilated cardiomyopathy	0.00163	0.00266	CcSEcCtD
Mesalazine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00163	0.00266	CcSEcCtD
Mesalazine—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00162	0.00264	CcSEcCtD
Mesalazine—Pneumonia—Lisinopril—dilated cardiomyopathy	0.0016	0.00262	CcSEcCtD
Mesalazine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.0016	0.00261	CcSEcCtD
Mesalazine—Depression—Lisinopril—dilated cardiomyopathy	0.00159	0.0026	CcSEcCtD
Mesalazine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00158	0.00259	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00158	0.00258	CcSEcCtD
Mesalazine—Rash—Spironolactone—dilated cardiomyopathy	0.00157	0.00257	CcSEcCtD
Mesalazine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00157	0.00256	CcSEcCtD
Mesalazine—Renal failure—Lisinopril—dilated cardiomyopathy	0.00157	0.00256	CcSEcCtD
Mesalazine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00156	0.00256	CcSEcCtD
Mesalazine—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00156	0.00255	CcSEcCtD
Mesalazine—Headache—Spironolactone—dilated cardiomyopathy	0.00156	0.00255	CcSEcCtD
Mesalazine—Jaundice—Lisinopril—dilated cardiomyopathy	0.00155	0.00254	CcSEcCtD
Mesalazine—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00155	0.00253	CcSEcCtD
Mesalazine—Anaemia—Furosemide—dilated cardiomyopathy	0.00153	0.00251	CcSEcCtD
Mesalazine—Sweating—Lisinopril—dilated cardiomyopathy	0.00153	0.0025	CcSEcCtD
Mesalazine—Haematuria—Lisinopril—dilated cardiomyopathy	0.00152	0.00248	CcSEcCtD
Mesalazine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00151	0.00246	CcSEcCtD
Mesalazine—Epistaxis—Lisinopril—dilated cardiomyopathy	0.0015	0.00246	CcSEcCtD
Mesalazine—Sinusitis—Lisinopril—dilated cardiomyopathy	0.0015	0.00244	CcSEcCtD
Mesalazine—Vertigo—Furosemide—dilated cardiomyopathy	0.00149	0.00244	CcSEcCtD
Mesalazine—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00149	0.00243	CcSEcCtD
Mesalazine—Leukopenia—Furosemide—dilated cardiomyopathy	0.00149	0.00243	CcSEcCtD
Mesalazine—Nausea—Spironolactone—dilated cardiomyopathy	0.00148	0.00242	CcSEcCtD
Mesalazine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00143	0.00234	CcSEcCtD
Mesalazine—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00143	0.00234	CcSEcCtD
Mesalazine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00142	0.00232	CcSEcCtD
Mesalazine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00141	0.00231	CcSEcCtD
Mesalazine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00141	0.0023	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.0014	0.00229	CcSEcCtD
Mesalazine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.0014	0.00229	CcSEcCtD
Mesalazine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00138	0.00226	CcSEcCtD
Mesalazine—Confusional state—Furosemide—dilated cardiomyopathy	0.00137	0.00223	CcSEcCtD
Mesalazine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00135	0.00221	CcSEcCtD
Mesalazine—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00135	0.00221	CcSEcCtD
Mesalazine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00133	0.00218	CcSEcCtD
Mesalazine—Shock—Furosemide—dilated cardiomyopathy	0.00133	0.00218	CcSEcCtD
Mesalazine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00133	0.00217	CcSEcCtD
Mesalazine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00133	0.00217	CcSEcCtD
Mesalazine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00132	0.00215	CcSEcCtD
Mesalazine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00131	0.00214	CcSEcCtD
Mesalazine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.0013	0.00212	CcSEcCtD
Mesalazine—Anorexia—Furosemide—dilated cardiomyopathy	0.00129	0.00211	CcSEcCtD
Mesalazine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00129	0.00211	CcSEcCtD
Mesalazine—Chills—Lisinopril—dilated cardiomyopathy	0.00128	0.0021	CcSEcCtD
Mesalazine—Hypotension—Furosemide—dilated cardiomyopathy	0.00127	0.00207	CcSEcCtD
Mesalazine—Alopecia—Lisinopril—dilated cardiomyopathy	0.00126	0.00207	CcSEcCtD
Mesalazine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00125	0.00205	CcSEcCtD
Mesalazine—Erythema—Lisinopril—dilated cardiomyopathy	0.00125	0.00204	CcSEcCtD
Mesalazine—Flatulence—Lisinopril—dilated cardiomyopathy	0.00123	0.00201	CcSEcCtD
Mesalazine—Tension—Lisinopril—dilated cardiomyopathy	0.00122	0.002	CcSEcCtD
Mesalazine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00122	0.00199	CcSEcCtD
Mesalazine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00122	0.00199	CcSEcCtD
Mesalazine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00121	0.00198	CcSEcCtD
Mesalazine—Back pain—Lisinopril—dilated cardiomyopathy	0.0012	0.00197	CcSEcCtD
Mesalazine—Somnolence—Furosemide—dilated cardiomyopathy	0.0012	0.00197	CcSEcCtD
Mesalazine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.0012	0.00196	CcSEcCtD
Mesalazine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00118	0.00193	CcSEcCtD
Mesalazine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00117	0.00192	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00117	0.00191	CcSEcCtD
Mesalazine—Fatigue—Furosemide—dilated cardiomyopathy	0.00117	0.00191	CcSEcCtD
Mesalazine—Tremor—Lisinopril—dilated cardiomyopathy	0.00117	0.00191	CcSEcCtD
Mesalazine—Constipation—Furosemide—dilated cardiomyopathy	0.00116	0.00189	CcSEcCtD
Mesalazine—Pain—Furosemide—dilated cardiomyopathy	0.00116	0.00189	CcSEcCtD
Mesalazine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00116	0.00189	CcSEcCtD
Mesalazine—Anaemia—Lisinopril—dilated cardiomyopathy	0.00115	0.00188	CcSEcCtD
Mesalazine—Angioedema—Lisinopril—dilated cardiomyopathy	0.00114	0.00186	CcSEcCtD
Mesalazine—Malaise—Lisinopril—dilated cardiomyopathy	0.00112	0.00184	CcSEcCtD
Mesalazine—Vertigo—Lisinopril—dilated cardiomyopathy	0.00112	0.00183	CcSEcCtD
Mesalazine—Syncope—Lisinopril—dilated cardiomyopathy	0.00112	0.00183	CcSEcCtD
Mesalazine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00112	0.00183	CcSEcCtD
Mesalazine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00111	0.00182	CcSEcCtD
Mesalazine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00111	0.00181	CcSEcCtD
Mesalazine—Palpitations—Lisinopril—dilated cardiomyopathy	0.0011	0.0018	CcSEcCtD
Mesalazine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00109	0.00179	CcSEcCtD
Mesalazine—Cough—Lisinopril—dilated cardiomyopathy	0.00109	0.00178	CcSEcCtD
Mesalazine—Urticaria—Furosemide—dilated cardiomyopathy	0.00108	0.00176	CcSEcCtD
Mesalazine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00107	0.00175	CcSEcCtD
Mesalazine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00107	0.00175	CcSEcCtD
Mesalazine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00106	0.00173	CcSEcCtD
Mesalazine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00106	0.00173	CcSEcCtD
Mesalazine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00106	0.00173	CcSEcCtD
Mesalazine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00106	0.00173	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00105	0.00172	CcSEcCtD
Mesalazine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00105	0.00171	CcSEcCtD
Mesalazine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00104	0.0017	CcSEcCtD
Mesalazine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00102	0.00168	CcSEcCtD
Mesalazine—Oedema—Lisinopril—dilated cardiomyopathy	0.00102	0.00166	CcSEcCtD
Mesalazine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00102	0.00166	CcSEcCtD
Mesalazine—Infection—Lisinopril—dilated cardiomyopathy	0.00101	0.00165	CcSEcCtD
Mesalazine—Shock—Lisinopril—dilated cardiomyopathy	0.001	0.00163	CcSEcCtD
Mesalazine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000998	0.00163	CcSEcCtD
Mesalazine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000995	0.00163	CcSEcCtD
Mesalazine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000992	0.00162	CcSEcCtD
Mesalazine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000987	0.00161	CcSEcCtD
Mesalazine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000983	0.00161	CcSEcCtD
Mesalazine—Asthenia—Furosemide—dilated cardiomyopathy	0.000972	0.00159	CcSEcCtD
Mesalazine—Anorexia—Lisinopril—dilated cardiomyopathy	0.000969	0.00158	CcSEcCtD
Mesalazine—Pruritus—Furosemide—dilated cardiomyopathy	0.000958	0.00157	CcSEcCtD
Mesalazine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00095	0.00155	CcSEcCtD
Mesalazine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000927	0.00152	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000926	0.00151	CcSEcCtD
Mesalazine—Insomnia—Lisinopril—dilated cardiomyopathy	0.000919	0.0015	CcSEcCtD
Mesalazine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000913	0.00149	CcSEcCtD
Mesalazine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000906	0.00148	CcSEcCtD
Mesalazine—Somnolence—Lisinopril—dilated cardiomyopathy	0.000904	0.00148	CcSEcCtD
Mesalazine—Dizziness—Furosemide—dilated cardiomyopathy	0.000896	0.00146	CcSEcCtD
Mesalazine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000895	0.00146	CcSEcCtD
Mesalazine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000884	0.00144	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000878	0.00143	CcSEcCtD
Mesalazine—Fatigue—Lisinopril—dilated cardiomyopathy	0.000876	0.00143	CcSEcCtD
Mesalazine—Constipation—Lisinopril—dilated cardiomyopathy	0.000869	0.00142	CcSEcCtD
Mesalazine—Pain—Lisinopril—dilated cardiomyopathy	0.000869	0.00142	CcSEcCtD
Mesalazine—Vomiting—Furosemide—dilated cardiomyopathy	0.000861	0.00141	CcSEcCtD
Mesalazine—Rash—Furosemide—dilated cardiomyopathy	0.000854	0.0014	CcSEcCtD
Mesalazine—Dermatitis—Furosemide—dilated cardiomyopathy	0.000853	0.0014	CcSEcCtD
Mesalazine—Headache—Furosemide—dilated cardiomyopathy	0.000849	0.00139	CcSEcCtD
Mesalazine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000838	0.00137	CcSEcCtD
Mesalazine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000831	0.00136	CcSEcCtD
Mesalazine—CHUK—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.000818	0.00218	CbGpPWpGaD
Mesalazine—IKBKB—BCR signaling pathway—RAF1—dilated cardiomyopathy	0.000812	0.00216	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000811	0.00216	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	0.000809	0.00215	CbGpPWpGaD
Mesalazine—IKBKB—Hair Follicle Development: Induction (Part 1 of 3)—EGFR—dilated cardiomyopathy	0.000809	0.00215	CbGpPWpGaD
Mesalazine—PPARG—Adipogenesis—AGT—dilated cardiomyopathy	0.000809	0.00215	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000808	0.00215	CbGpPWpGaD
Mesalazine—Urticaria—Lisinopril—dilated cardiomyopathy	0.000808	0.00132	CcSEcCtD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—CD36—dilated cardiomyopathy	0.000805	0.00214	CbGpPWpGaD
Mesalazine—Nausea—Furosemide—dilated cardiomyopathy	0.000805	0.00132	CcSEcCtD
Mesalazine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000804	0.00131	CcSEcCtD
Mesalazine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000804	0.00131	CcSEcCtD
Mesalazine—CHUK—Toll-Like Receptors Cascades—CD36—dilated cardiomyopathy	0.000791	0.0021	CbGpPWpGaD
Mesalazine—CHUK—TNF receptor signaling pathway —TNF—dilated cardiomyopathy	0.00079	0.0021	CbGpPWpGaD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	0.000788	0.0021	CbGpPWpGaD
Mesalazine—IKBKB—TWEAK Signaling Pathway—TNF—dilated cardiomyopathy	0.000771	0.00205	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.000763	0.00203	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—RAC1—dilated cardiomyopathy	0.000754	0.00201	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—SDHA—dilated cardiomyopathy	0.00075	0.002	CbGpPWpGaD
Mesalazine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000749	0.00122	CcSEcCtD
Mesalazine—CHUK—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.000748	0.00199	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	0.000745	0.00198	CbGpPWpGaD
Mesalazine—IKBKB—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.000742	0.00198	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000735	0.00196	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000735	0.00196	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000733	0.00195	CbGpPWpGaD
Mesalazine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000729	0.00119	CcSEcCtD
Mesalazine—Pruritus—Lisinopril—dilated cardiomyopathy	0.000719	0.00118	CcSEcCtD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000717	0.00191	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—CD36—dilated cardiomyopathy	0.000717	0.00191	CbGpPWpGaD
Mesalazine—IKBKB—TNF receptor signaling pathway —TNF—dilated cardiomyopathy	0.000717	0.00191	CbGpPWpGaD
Mesalazine—CHUK—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000707	0.00188	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.000705	0.00188	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000701	0.00187	CbGpPWpGaD
Mesalazine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000695	0.00114	CcSEcCtD
Mesalazine—CHUK—TNF alpha Signaling Pathway—RAF1—dilated cardiomyopathy	0.000695	0.00185	CbGpPWpGaD
Mesalazine—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.000693	0.00184	CbGpPWpGaD
Mesalazine—CHUK—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.000685	0.00182	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—RAC1—dilated cardiomyopathy	0.000683	0.00182	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000682	0.00181	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.000678	0.0018	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.000676	0.0018	CbGpPWpGaD
Mesalazine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000672	0.0011	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.000668	0.00178	CbGpPWpGaD
Mesalazine—CHUK—B Cell Receptor Signaling Pathway—RAF1—dilated cardiomyopathy	0.000666	0.00177	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000664	0.00177	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—RAC1—dilated cardiomyopathy	0.00066	0.00176	CbGpPWpGaD
Mesalazine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000646	0.00106	CcSEcCtD
Mesalazine—IKBKB—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000641	0.00171	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000641	0.00171	CbGpPWpGaD
Mesalazine—Rash—Lisinopril—dilated cardiomyopathy	0.000641	0.00105	CcSEcCtD
Mesalazine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00064	0.00105	CcSEcCtD
Mesalazine—Headache—Lisinopril—dilated cardiomyopathy	0.000637	0.00104	CcSEcCtD
Mesalazine—PPARG—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000635	0.00169	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—RAF1—dilated cardiomyopathy	0.00063	0.00168	CbGpPWpGaD
Mesalazine—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000624	0.00166	CbGpPWpGaD
Mesalazine—CHUK—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	0.000622	0.00165	CbGpPWpGaD
Mesalazine—IKBKB—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.000621	0.00165	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—FASLG—dilated cardiomyopathy	0.000621	0.00165	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000621	0.00165	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000621	0.00165	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000618	0.00165	CbGpPWpGaD
Mesalazine—CHUK—Rac1/Pak1/p38/MMP-2 pathway—EGFR—dilated cardiomyopathy	0.000614	0.00164	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—RAF1—dilated cardiomyopathy	0.000611	0.00163	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—RAC1—dilated cardiomyopathy	0.000611	0.00163	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000609	0.00162	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—RAF1—dilated cardiomyopathy	0.000604	0.00161	CbGpPWpGaD
Mesalazine—Nausea—Lisinopril—dilated cardiomyopathy	0.000604	0.000987	CcSEcCtD
Mesalazine—PPARG—Signaling events mediated by HDAC Class I—TNF—dilated cardiomyopathy	0.000602	0.0016	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	0.000599	0.00159	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000596	0.00159	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.000587	0.00156	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000584	0.00156	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000579	0.00154	CbGpPWpGaD
Mesalazine—IKBKB—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	0.000564	0.0015	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000563	0.0015	CbGpPWpGaD
Mesalazine—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—dilated cardiomyopathy	0.000558	0.00148	CbGpPWpGaD
Mesalazine—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—EGFR—dilated cardiomyopathy	0.000557	0.00148	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—RAF1—dilated cardiomyopathy	0.000554	0.00148	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ANKRD1—dilated cardiomyopathy	0.000546	0.00145	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—TAZ—dilated cardiomyopathy	0.000513	0.00137	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.000509	0.00135	CbGpPWpGaD
Mesalazine—CHUK—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.000503	0.00134	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.000494	0.00131	CbGpPWpGaD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000492	0.00131	CbGpPWpGaD
Mesalazine—CHUK—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000488	0.0013	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—TNF—dilated cardiomyopathy	0.000488	0.0013	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—NR3C2—dilated cardiomyopathy	0.000487	0.0013	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000486	0.00129	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000473	0.00126	CbGpPWpGaD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000468	0.00125	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000465	0.00124	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—SDHA—dilated cardiomyopathy	0.000464	0.00124	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000458	0.00122	CbGpPWpGaD
Mesalazine—CHUK—TNF alpha Signaling Pathway—TNF—dilated cardiomyopathy	0.000454	0.00121	CbGpPWpGaD
Mesalazine—CHUK—PI-3K cascade—EGFR—dilated cardiomyopathy	0.000453	0.00121	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000446	0.00119	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000444	0.00118	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000443	0.00118	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TNF—dilated cardiomyopathy	0.000443	0.00118	CbGpPWpGaD
Mesalazine—CHUK—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000442	0.00118	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000442	0.00118	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.00044	0.00117	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.00044	0.00117	CbGpPWpGaD
Mesalazine—CHUK—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000439	0.00117	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	0.000438	0.00117	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000438	0.00117	CbGpPWpGaD
Mesalazine—CHUK—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000429	0.00114	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000423	0.00113	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—TNF—dilated cardiomyopathy	0.000418	0.00111	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000412	0.0011	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000412	0.0011	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000412	0.0011	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—TNF—dilated cardiomyopathy	0.000412	0.0011	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000408	0.00109	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000405	0.00108	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000405	0.00108	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000403	0.00107	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000401	0.00107	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	0.000389	0.00104	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000387	0.00103	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000384	0.00102	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000383	0.00102	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—TNF—dilated cardiomyopathy	0.000379	0.00101	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000373	0.000994	CbGpPWpGaD
Mesalazine—PPARG—Adipogenesis—TNF—dilated cardiomyopathy	0.000367	0.000976	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000366	0.000975	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000365	0.000971	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000362	0.000964	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TAZ—dilated cardiomyopathy	0.00036	0.000957	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000353	0.00094	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	0.000351	0.000934	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000346	0.000921	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000339	0.000902	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TNF—dilated cardiomyopathy	0.000326	0.000869	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SDHA—dilated cardiomyopathy	0.000325	0.000866	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000324	0.000863	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000321	0.000854	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000319	0.000849	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—CD36—dilated cardiomyopathy	0.000309	0.000822	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—NPPA—dilated cardiomyopathy	0.000306	0.000814	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000305	0.000811	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000304	0.000808	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000303	0.000807	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000302	0.000803	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—EGFR—dilated cardiomyopathy	0.0003	0.000799	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TNF—dilated cardiomyopathy	0.000296	0.000788	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.000296	0.000787	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—RAC1—dilated cardiomyopathy	0.000291	0.000775	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000288	0.000767	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TAZ—dilated cardiomyopathy	0.000286	0.00076	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	0.000285	0.000759	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000283	0.000754	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000282	0.000752	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000282	0.000752	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000282	0.000752	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000281	0.000747	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.00028	0.000745	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	0.000279	0.000742	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000277	0.000738	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000276	0.000735	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000276	0.000734	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.000268	0.000714	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	0.000267	0.000711	CbGpPWpGaD
Mesalazine—CHUK—Disease—NPPA—dilated cardiomyopathy	0.000266	0.000709	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000266	0.000707	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000261	0.000696	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—EGFR—dilated cardiomyopathy	0.000261	0.000696	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	0.000259	0.000689	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SDHA—dilated cardiomyopathy	0.000258	0.000687	CbGpPWpGaD
Mesalazine—CHUK—Disease—PSEN2—dilated cardiomyopathy	0.000258	0.000687	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000256	0.000682	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CD36—dilated cardiomyopathy	0.000256	0.000682	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000254	0.000677	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	0.000254	0.000677	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000253	0.000674	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.00025	0.000666	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000248	0.000661	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000246	0.000655	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—RAC1—dilated cardiomyopathy	0.000241	0.000642	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—EGFR—dilated cardiomyopathy	0.000237	0.000631	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CD36—dilated cardiomyopathy	0.000232	0.000618	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000232	0.000617	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.000231	0.000616	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.00023	0.000611	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000223	0.000593	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.00022	0.000587	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—RAC1—dilated cardiomyopathy	0.000219	0.000582	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.00021	0.000559	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GPX1—dilated cardiomyopathy	0.000204	0.000542	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—CD36—dilated cardiomyopathy	0.000198	0.000528	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000198	0.000528	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000193	0.000514	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—RAF1—dilated cardiomyopathy	0.000193	0.000514	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000192	0.000512	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000181	0.000481	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AGT—dilated cardiomyopathy	0.000179	0.000476	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ITGB1—dilated cardiomyopathy	0.000175	0.000465	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000174	0.000464	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000174	0.000463	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000164	0.000436	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00016	0.000427	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00016	0.000427	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—RAF1—dilated cardiomyopathy	0.00016	0.000426	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ITGB1—dilated cardiomyopathy	0.000159	0.000422	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NPPA—dilated cardiomyopathy	0.000158	0.00042	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000157	0.000419	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000157	0.000419	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000154	0.000409	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000153	0.000408	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PSEN2—dilated cardiomyopathy	0.000153	0.000407	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.00015	0.000399	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000149	0.000397	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD36—dilated cardiomyopathy	0.000149	0.000397	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000145	0.000387	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000145	0.000387	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—RAF1—dilated cardiomyopathy	0.000145	0.000386	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000144	0.000385	CbGpPWpGaD
Mesalazine—CHUK—Immune System—RAC1—dilated cardiomyopathy	0.000141	0.000374	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000139	0.000371	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000138	0.000368	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000135	0.00036	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD36—dilated cardiomyopathy	0.000135	0.00036	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EGFR—dilated cardiomyopathy	0.000132	0.000352	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000131	0.000349	CbGpPWpGaD
Mesalazine—CHUK—Disease—RAC1—dilated cardiomyopathy	0.00013	0.000345	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RAC1—dilated cardiomyopathy	0.000127	0.000339	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GPX1—dilated cardiomyopathy	0.000126	0.000336	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—dilated cardiomyopathy	0.000126	0.000335	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000123	0.000328	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CD36—dilated cardiomyopathy	0.000123	0.000327	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000117	0.000312	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000112	0.000298	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AGT—dilated cardiomyopathy	0.000111	0.000294	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—dilated cardiomyopathy	0.00011	0.000292	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000106	0.000283	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—dilated cardiomyopathy	0.000105	0.00028	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000101	0.000268	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—dilated cardiomyopathy	9.95e-05	0.000265	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—dilated cardiomyopathy	9.55e-05	0.000254	CbGpPWpGaD
Mesalazine—CHUK—Immune System—RAF1—dilated cardiomyopathy	9.32e-05	0.000248	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.12e-05	0.000243	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RAC1—dilated cardiomyopathy	9.09e-05	0.000242	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GPX1—dilated cardiomyopathy	8.84e-05	0.000235	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AGT—dilated cardiomyopathy	8.68e-05	0.000231	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CD36—dilated cardiomyopathy	8.6e-05	0.000229	CbGpPWpGaD
Mesalazine—CHUK—Disease—RAF1—dilated cardiomyopathy	8.6e-05	0.000229	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RAF1—dilated cardiomyopathy	8.45e-05	0.000225	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RAC1—dilated cardiomyopathy	8.24e-05	0.000219	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AGT—dilated cardiomyopathy	7.87e-05	0.00021	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AGT—dilated cardiomyopathy	7.75e-05	0.000206	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RAC1—dilated cardiomyopathy	7.69e-05	0.000205	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPX1—dilated cardiomyopathy	7.01e-05	0.000187	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CD36—dilated cardiomyopathy	6.83e-05	0.000182	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—dilated cardiomyopathy	6.39e-05	0.00017	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AGT—dilated cardiomyopathy	6.15e-05	0.000164	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RAF1—dilated cardiomyopathy	6.03e-05	0.00016	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—dilated cardiomyopathy	5.9e-05	0.000157	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—dilated cardiomyopathy	5.79e-05	0.000154	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RAF1—dilated cardiomyopathy	5.46e-05	0.000145	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RAF1—dilated cardiomyopathy	5.1e-05	0.000136	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—dilated cardiomyopathy	4.13e-05	0.00011	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—dilated cardiomyopathy	3.75e-05	9.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—dilated cardiomyopathy	3.5e-05	9.3e-05	CbGpPWpGaD
